Clinical trials: Solid Organ Transplantation Recipient
Cytomegalovirus Infections, Infection in Solid Organ Transplant Recipients
Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients
This is a research study to test the tolerability and clinical effectiveness of the study drug, Letermovir (LET), when used as secondary prophylaxis following treatment of Cytomegalovirus (CMV) infection and disease in a solid…
- Conditions
- Cytomegalovirus Infections, Infection in Solid Organ Transplant Recipients, Neutropenia, Antiviral Toxicity
- Trial name
- NCT05626530
- Testing
- Letermovir
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Tufts Medical Center
Cytomegalovirus (CMV) Infection
CytoGam for CMV Infection or Disease in Solid Organ Transplant Recipients
Cytomegalovirus (CMV) is a significant opportunistic pathogen and a major cause of morbidity and mortality in solid organ transplant recipients.
- Trial name
- NCT07009548
- Testing
- Cytogam
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Fernanda P Silveira, MD, MS
CMV Infection
Study Evaluating the Efficacy and Safety of Artesunate
This study is a randomized, open-label, active comparator-controlled, dose-ranging trial of the efficacy and safety of IV artesunate in combination with IV GCV or oral VGCV and SOC treatment compared to GCV or VGCV monotherapy…
- Trial name
- NCT06853184
- Testing
- Artesunate, Ganciclovir (GCV)
- Where
- 4 sites in United States, Australia
- Volunteers
- 90 people
- Sponsor
- Amivas Inc.
Complications of Transplanted Organs and Tissue
Identification and Treatment of Diabetes In Solid Organ Transplant Recipients
The purpose of this study is to determine the influence of post-transplant diabetes on medical and psychosocial outcomes in individuals who receive solid-organ transplant prior to 18 years of age and their families.
- Trial name
- NCT02605200
- Testing
- Psychologist Support, Pediatric Certified Diabetes Educators (CDEs) Support
- Where
- 2 sites in United States
- Volunteers
- 65 people
- Sponsor
- Emory University
Infection in Solid Organ Transplant Recipients
The Incidence and Risk Factors for Clostridioides Difficle Infection in Solid Organ Transplant Recipients
2.1. Study Objectives Primary Objective(s) Identify the incidence and risk of CDI within one year after kidney, liver, and/or pancreas transplant Secondary Objective(s) Identify the risk factors for recurrent CDI post-transplant…
- Trial name
- NCT04637321
- Testing
- Solid organ transplant
- Where
- United States
- Volunteers
- 585 people
- Sponsor
- Methodist Health System
Transplant
Cell Mediated Immunity and the Prediction of CMV Infection In Solid Organ Transplant Recipients
Cytomegalovirus (CMV) is a common cause of illness in patients who have undergone a transplant. Serious infections due to CMV can affect many parts of the body including the lungs, the gut, and the liver.
- Trial name
- NCT00436384
- Testing
- Monitoring-blood samples drawn for CMV testing
- Where
- Canada
- Volunteers
- 150 people
- Sponsor
- University Health Network, Toronto
Heart Transplant Infection, Kidney Transplant Infection
CMV T Cell Immunity in Pediatric Solid Organ Transplant Recipients
CMV infection and disease remain a significant clinical challenge for pediatric solid organ transplant (SOT) recipients. Current prevention strategies are limited to prophylaxis in which antiviral medication is administered for a…
- Conditions
- Heart Transplant Infection, Kidney Transplant Infection, Liver Transplant Infection, CMV
- Trial name
- NCT03924219
- Testing
- CMV T cell Immunity Assay
- Where
- 12 sites in United States
- Volunteers
- 161 people
- Sponsor
- Vanderbilt University Medical Center
Vaccine Response Impaired, Immune Suppression
Third Dose of Moderna COVID-19 Vaccine in Transplant Recipients
This study will be a randomized, double-blind, placebo-controlled trial of a third dose of Moderna vaccine versus placebo. Participants will be those that have received two doses of mRNA-1273 COVID vaccine (Moderna) at 0 and 1…
- Conditions
- Vaccine Response Impaired, Immune Suppression, Covid19
- Trial name
- NCT04885907
- Testing
- mRNA-1273 vaccine
- Where
- 2 sites in Canada
- Volunteers
- 120 people
- Sponsor
- University Health Network, Toronto
Monitoring, Immunologic, Active Tuberculosis
New Generation IGRA in Immunocompromised Individuals
Evaluation of a new ELISA based interferon-gamma release assay (QuantiFERON TB plus In-tube test) in immunocompromized patients
- Conditions
- Monitoring, Immunologic, Active Tuberculosis, Tuberculosis in Solid Organ Transplant Recipients, Tuberculosis in Marrow Transplant Recipients
- Trial name
- TBnet#54 (NCT02639936)
- Where
- 16 sites in Denmark, Germany and 8 more
- Volunteers
- 2,663 people, healthy volunteers welcome
- Sponsor
- Tuberculosis Network European Trialsgroup
Graft vs Host Disease, Kidney Transplantation
Study Evaluating Sirolimus (Rapamune™) in Solid Organ Transplant Recipients
To evaluate the safety of long-term administration of sirolimus oral solution for up to 5 additional years, or until the tablet formulation is commercially available (whichever occurs first) in solid organ transplant recipients…
- Trial name
- NCT00037531
- Testing
- Sirolimus (RAPAMUNE)
- Where
- 20 sites in United States, Canada
- Volunteers
- 769 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Cytomegalovirus Viraemia
Cell-Mediated Immunity Based Primary Prophylaxis for CMV Infection in Organ Transplant Recipients
The study will prospectively determine the clinical utility of CMV cell-mediated immunity using the Quantiferon test. The investigators will use the assay results to tailor the duration of CMV prophylaxis in solid organ…
- Trial name
- QFT-CMV (NCT02784756)
- Testing
- Quantiferon-CMV assay
- Where
- 6 sites in Canada, Spain
- Volunteers
- 134 people
- Sponsor
- University Health Network, Toronto
CMV Infection
HORUS-Cytomegalovirus Open Proof-of-concept Exploratory Trial
Cytomegalovirus (CMV) remains a significant cause of morbidity and mortality following organ transplantation. Cell-mediated immunity plays a crucial role in controlling CMV replication after transplantation.
- Trial name
- HORUS-COPE (NCT07570433)
- Testing
- 50% reduction in the dose of MPA, Switch from MPA to a mammalian target of rapamycin inhibitor (mTORi), together with an adapted dose of tacrolimus, standard antiviral therapy along with maintenance of their initial immunosuppressive therapy.
- Where
- 4 sites in France, Spain and 1 more
- Volunteers
- 100 people
- Sponsor
- Oriol Manuel
Solid Organ Transplant Rejection, Chronic Kidney Failure
Exercise Training and Kidney Transplantation
The goal of this clinical trial is to investigate the physiological and molecular effects of exercise training in transplant recipients. The main questions it aims to answer are: 1.
- Conditions
- Solid Organ Transplant Rejection, Chronic Kidney Failure, Quality of Life, Inflammation
- Trial name
- EXTRA (NCT06216015)
- Testing
- Exercise training, Continue exercising, Discontinue exercising
- Volunteers
- 345 people
- Sponsor
- Hugo de Luca Correa
Solid Organ Transplant Recipient, Skin Cancer
The Organ Transplant Recipient HPV and Skin Cancer Study
Solid organ transplant recipients (OTRs) receive lifelong immunosuppressive therapy, which puts them at increased risk of cutaneous and mucosal cancers.
- Conditions
- Solid Organ Transplant Recipient, Skin Cancer, Skin Dysplasia, HPV Infection
- Trial name
- NCT05284877
- Testing
- No intervention
- Where
- 3 sites in Denmark
- Volunteers
- 1,500 people
- Sponsor
- Merete Haedersdal
Cytomegalovirus Infection
Quantiferon - Cytomegalovirus (CMV) and the Prediction of CMV Infection In High Risk Solid Organ Transplant Recipients
Cytomegalovirus (CMV) is a common cause of illness in patients who have undergone a transplant. Serious infections due to CMV can affect many parts of the body including the lungs, the gut, and the liver.
- Trial name
- NCT00817908
- Where
- Canada
- Volunteers
- 131 people
- Sponsor
- University of Alberta
EBV Viremia, CMV Viremia
Treating Kidney Donors With Valganciclovir to Reduce Viral Transmission to Recipients
The aim of our study is to reduce viral (CMV and EBV) transmission from donor to recipient. The discovery that anti-retroviral therapy to mothers with HIV reduced transmission of the virus to their babies was pivotal to the…
- Trial name
- NCT01329185
- Testing
- Valganciclovir
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Minnesota
Infection in Solid Organ Transplant Recipients
Clinical Trial Evaluating Efficacy and Safety of One Dose Versus Two Doses of Influenza Vaccination
Randomized, multicenter, open label trial to compare safety and efficacy of two doses stationary flu vaccination vs one doses in Solid Organ Transplant Recipients.
- Trial name
- TraNsgripe (NCT01761435)
- Testing
- Influenza vaccine
- Where
- 12 sites in Spain
- Volunteers
- 499 people
- Sponsor
- Fundación Pública Andaluza Progreso y Salud
Cytomegalovirus Infections, Varicella Zoster Virus Infection
Herpesvirus Immunology in Solid Organ Transplant Recipients - Liver Transplant Study
Liver transplantation is the only curative treatment of end-stage liver disease, and every year, around 60 patients undergo liver transplantation in Denmark.
- Conditions
- Cytomegalovirus Infections, Varicella Zoster Virus Infection, Liver Transplant; Complications
- Trial name
- HISTORY (NCT05532540)
- Where
- 3 sites in Denmark
- Volunteers
- 80 people
- Sponsor
- Susanne Dam Nielsen, MD, DMSc
Solid Organ Transplant, Fusariosis
Fusariosis in Solid-Organ Transplant Recipients
This exempt chart review study will try to determine the clinical presentation, prognostic factors, response to different treatment modalities and mortality among patients diagnosed with fusariosis after solid-organ…
- Trial name
- NCT00518778
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Pittsburgh
Solid Organ Transplant Complications, Solid Organ Transplant Recipients
Phase I Trial on the Safety of Delayed Infusion of a Naïve T Cell-Depleted Hematopoietic Graft With Memory T Cells in Solid Organ Transplant Recipients
The goal of this clinical trial is to evaluate the safety and feasibility of inducing hematopoietic mixed chimerism to promote immune tolerance and potentially reduce the need for lifelong immunosuppression in pediatric and adult…
- Conditions
- Solid Organ Transplant Complications, Solid Organ Transplant Recipients, Solid Organ Transplant Rejection
- Trial name
- DUALGRAFT (NCT06997471)
- Testing
- Investigational cellular therapy consisting on a HSCT using a graft enriched in CD34+, depleted of naïve T-lymphocytes and supplemented with memory lymphocytes
- Where
- Spain
- Volunteers
- 10 people
- Sponsor
- Francisco Hernández Oliveros